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Understanding the interactions between small molecules and proteins can be approached from different per-
spectives and is important for the advancement of basic science and drug development. Chemists often use
bioactive small molecules, such as natural products or synthetic compounds, as probes to identify therapeu-
tically relevant protein targets. Biochemists and biologists often begin with a specific protein and seek to
identify the endogenous metabolites that bind to it. These interests have led to the development of method-
ology that relies heavily on synthetic and analytical chemistry to identify protein-small molecule and protein-
metabolite interactions. Here, we survey these strategies, highlighting key findings, to demonstrate the value
of these approaches in answering important chemical and biological questions.Introduction
A number of different types of molecular interactions enable life.
These include the interactions between proteins, proteins and
nucleic acids, and proteins and small molecules. Elucidating
these interactions and understanding how they control biology
is a major scientific goal. A number of approaches have been
developed in recent years to identify protein-protein interactions
(Gingras et al., 2007; Uetz et al., 2000; Frei et al., 2012; Kaushan-
sky et al., 2010; Hubner et al., 2010; Glatter et al., 2009) and pro-
tein-nucleic acid interactions (Ingolia et al., 2009, 2012; Johnson
et al., 2007). Ribosome profiling, for example, elucidates interac-
tions between the ribosome andRNA in cells to reveal novel sites
of protein translation. While many methods exist for the charac-
terization of biopolymer interactions, far fewer approaches exist
to elucidate interactions between proteins and small molecules.
In recent years, however, more of these methods are beginning
to emerge.
The importance of protein-small molecule interactions (PSMIs)
in drug discovery and protein-metabolite interactions (PMIs) in
biology has driven the development of new methods that rely
heavily on the integration of both synthetic chemistry and analyt-
ical chemistry. Here, we divide these methods into two cate-
gories: small molecule-to-protein and protein-to-small molecule
strategies. This division separates problems that aim to identify
the protein targets of a bioactive small molecule from problems
focused on identifying the small molecule-binding partner of a
suspected metabolite-binding protein.
Small Molecule to Protein
Small Molecule Affinity Methods
One of the successes in using small molecules as affinity
reagents is the identification of FK506 binding protein by the
natural product FK506 (Harding et al., 1989). This seminal work
led to the discovery of new proteins and pathways that explained
the mechanism of action of a potent class of immunosuppres-
sant drugs (Schreiber and Crabtree, 1992). In doing so, thisChemistry & Bwork informed us about vital but previously unknown cellular
pathways involved in the regulation of the cellular immune
response. More generally, these studies highlighted the tremen-
dous value of using bioactive small molecules to study biology.
Other important examples, including the discovery of the histone
deacetylase family with trapoxin (Taunton et al., 1996), rein-
forced the impact of chemistry in important biological discov-
eries, leading to the development of the field of chemical biology
(Kijima et al., 1993). All of this is predicated on being able to use
complex bioactive small molecules as affinity reagents, which
often requires complex chemical syntheses and emphasizes
the importance of organic chemistry in this problem.
The increased use of small molecule screening approaches in
biology has led to the identification of many bioactive molecules,
leading to an increased demand for methods that can elucidate
PSMIs. Affinity-based methods are still the most common
approach used, and leading methods have learned to integrate
these approaches with modern proteomics to accelerate tar-
geted discovery. Ong and colleagues, for example, have com-
bined small molecule-affinity chromatography with stable
isotope labeling of amino acids in cell culture (SILAC) (Ong
et al., 2002), a quantitative mass spectrometry (MS)-based pro-
teomics strategy (using an ion trap MS), to identify PSMIs on a
proteome-wide scale (Ong et al., 2002, 2009; Figure 1). To
demonstrate the generality of this approach, seven different
compounds, including kinase inhibitors and immunophilin
ligands, were studied in this first example. Derivatives of each
of these compounds were prepared and linked to solid support
by a carbamate linkage, affording small molecule, derivatized
beads.
In SILAC, cells are then grown in regular media (light) or
specialized media (heavy) that replaces certain amino acids
with stable isotope labeled derivatives (e.g., 13C6-arginine and
13C6,15N2-lysine). The result is that the proteins in the ‘‘heavy’’
cells have proteins that weighmore than the exact same proteins
in ‘‘light’’ cells, and these proteins can be distinguished andiology 20, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 667
Figure 1. Affinity Capture Coupled to SILAC for Small Molecule
Target Identification
Cells are grown in heavy or light media and subsequently lysed. These heavy
and light cell lysates are separately incubated with beads that are modified
with a small molecule of interest. Excess small molecule is added to the light
cell lysate, and this soluble small molecule prevents any specific small
molecule-protein interactions with the beads. After removal of the lysate,
bound proteins are eluted from the beads and the lysates are then combined
for subsequent analysis using quantitative proteomics. The samples can be
distinguished by mass spectrometry, since proteins from each sample have
different molecular weights, and therefore specific PMSIs can be identified by
the higher concentrations of these heavy proteins versus light proteins.
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PSMIs by passing light lysate over beads coated with the bioac-
tive small molecule. Any proteins with affinity for the small mole-
cule are retained. As a control, a soluble variant of the small
molecule is added to the heavy lysate before it is incubated
with the small molecule-modified beads. This soluble compound
has the effect of binding the target proteins and preventing their
binding to the small molecules on the surface of the bead. The
postbead lysate samples are then combined and analyzed by
mass spectrometry. The ratio of light to heavy can identify those
proteins that are specifically enriched by the small molecule on
the bead and therefore identify any target proteins of the small
molecule.
The results from these initial experiments were excellent. All
the compounds used identified known PSMIs, and several re-
vealed some novel interactions. Moreover, by using compounds
with different affinities for their targets, this work demonstrated
that this method can successfully identify PSMIs with affinities
from the low nanomolar (26 nM) to micromolar (44 mM) range.
This strategy has been applied to the identification of the primary668 Chemistry & Biology 20, May 23, 2013 ª2013 Elsevier Ltd All rightargets of piperlongumine (Raj et al., 2011), a compound that was
shown to selectively kill cancer cells in vitro and in vivo by target-
ing the stress response to reactive oxygen species (Adams et al.,
2012). Overall, these types of affinity approaches have come to
dominate themethods that are used to identify PMSIs. Examples
include the identification of the nucleophosmin as a target of
natural product avrainvillamide (Wulff et al., 2007) and the finding
that cephalostatin A binds specifically to members of the oxy-
sterol-binding proteins, in the process revealing these proteins
to be important in cancer cell proliferation (Burgett et al., 2011).
Importantly, affinity methods are not limited to synthetic
compounds or natural products but can also be used with
endogenous metabolites. Specifically, Nachtergaele and col-
leagues demonstrated a direct binding interaction between
20(S)-hydroxycholesterol and the oncoprotein smoothened, a
key protein in the sonic hedgehog pathway, using a derivative
of 20(S)-hydroxycholesterol (nat-20(S)-yne) that was immobi-
lized onto a solid support using Sharpless’ click chemistry
(Nachtergaele et al., 2012). This example highlights the general-
ity of affinity-based approaches in identifying PSMIs. The only
limitation appears to be the ability to access derivatives for
immobilization by chemical synthesis and compounds that
have or retain high affinity for their protein target. As scientists
continue to gain interest in understanding themechanism under-
lying bioactive small molecules, affinity-based methods will
continue to be applied to many more target molecules.
Proteomic Target Identification
In cases where small molecules are difficult to modify or the
synthetic skill necessary to make such modifications is difficult
to access, a new group of powerful proteomics methods to
discover novel PSMIs can be used. These strategies rely on
detecting differences in the stability between unbound and small
molecule-bound proteins to identify the target(s) of a small mole-
cule. Drug affinity responsive target stability (DARTS) is one such
method (Lomenick et al., 2009).
DARTS relies on the fact that proteins are more stable when
bound to a metabolite, which makes them less susceptible to
proteolysis. Lysates are compared in the presence and absence
of a small molecule. Proteins that bind to the small molecule are
protected from proteolysis relative to the control sample, as indi-
cated by mass spectrometry (Figure 2). Proof-of-concept exper-
iments revealed that mammalian target of rapamycin (mTOR), for
example, is less susceptible to proteolysis in the presence of E4,
an mTOR kinase inhibitor. Moreover, DARTS is generally appli-
cable and was used with other enzyme-inhibitor pairs, such as
the cyclooxygenase 2-celecoxib pair.
Next, DARTS was used to characterize PSMIs for resveratrol,
an antiaging compound thought to act primarily through interac-
tions with the sirtuin protein Sir1. Using a yeast and human
lysates, the authors discovered that eukaryotic initiation factor
A (eIF4A) is a target of resveratrol, which demonstrates that
DARTS is able to discover novel PSMIs. Importantly, the authors
confirmed that at least some of the biology controlled by resver-
atrol is eIF4A dependent, because worms lacking eIF4A no
longer show any antiaging in the presence of resveratrol.
Together these experiments demonstrate the value and utility
of DARTS for discovering PSMIs.
Most recently, a proteomics method called stability of proteins
from rates of oxidation (SPROX) was developed to identifyts reserved
Figure 3. Stability of Proteins from Rates of Oxidation
SPROX identifies the targets of a small molecule from a complex protein
mixture by measuring the ligand-induced changes in the rate of methionine
amino acid side chain oxidation by hydrogen peroxide. Aliquots of the cell
lysate are incubated with either a small molecule or a solvent control and then
incubated with increasing concentrations of guanidine hydrochloride. Ligand-
induced difference in target protein unfolding will impact the rate of selective
methionine oxidation by hydrogen peroxide. Quantitative proteomic is used to
compare levels of reduced versus oxidized methionine-containing peptides in
each sample set (small molecule versus control) to determine the rate of target
protein oxidation as a function of guanidine hydrochloride concentration. A
shift of the transition midpoint for a protein between + ligand and  ligand
samples indicates that the protein is a target for the small molecule in lysate.
Figure 2. Drug Affinity Responsive Target Stability
Aliquots of a protein lysate are mixed with either a small molecule (+ ligand) or
solvent control (ligand) to identify PSMIs. These samples are then subjected
to limited proteolysis and compared by gel electrophoresis and quantitative
mass spectrometry. Protein targets are identified as those proteins that
display increased protease resistance in the presence of the small molecule.
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et al., 2013; Dearmond et al., 2011). Rather than relying on
nonspecific proteolysis, which can make downstream mass
spectrometry experiments difficult to interpret, SPROX relies
on the irreversible oxidation of methionine residues by hydrogen
peroxide to report on the thermodynamic stability of a protein’s
structure during chemical denaturation (Figure 3). Proof-of-
concept SPROX experiments performed using yeast lysates
validated this approach by identifying known binders of the
immunosuppressant drug cyclosporine A (West et al., 2010).
SPROX has also been used with resveratrol, identifying the
known target, cytosolic aldehyde dehydrogenase, along with
several novel interactions (Dearmond et al., 2011). SPROX
requires that target proteins contain methionine residues, and
multidimensional protein identification technology (Washburn
et al., 2001; Delahunty and Yates, 2007) analysis of SPROX
experiments using yeast lysates demonstrated that 33% of the
detectable proteins contain a methionine.
A SPROX-like method that uses s-methyl thioacetimidate
(SMTA) labeling to detect amidination differences of proteins
and protein-ligand complexes during chemical denaturationChemistry & Bhas also been explored (Xu et al., 2011). This method requires
target proteins to contain lysine residues or have a buried
N terminus in the native state. This method is particularly useful
when a ligand of interest is not stable in hydrogen peroxide and
therefore cannot be investigated by SPROX. SMTA labeling and
SPROX complement each other, covering a wider range of the
proteome (Xu et al., 2011). Studying the thermodynamic stability
of proteins under denaturing conditions in the presence and
absence of ligand is an effective target protein identification
strategy. However, the two described approaches require rela-
tively large concentrations of ligand in the mM to mM range,
although they provide the flexibility to use a variety of down-
stream quantitative proteomic techniques.
Chemoproteomic Target Identification
Unfortunately, not all proteins are as active in lysates as they are
within the context of a cell, and therefore, some relevant PSMIs
or PMIsmay bemissedwhen using lysates. Screening a spiroep-
oxide library for antiproliferative compounds, for example,
revealed that themost relevant biological target of the active spi-
roepoxide is only targeted in a living cell but was inactive once
the cell was lysed (Evans et al., 2005). Many molecular mecha-
nisms can account for the difference between intact cells and
lysates, but the ultimate point is that it is difficult to exactly repli-
cate cellular conditions in any type biochemical experiment.
Since it is impossible to predict what PSMIs are sensitive
to cellular conditions, new chemoproteomic approaches have
been developed to enable target identification within live cells.
These methods rely on the use of small molecules that can
covalently label their protein targets so that intracellular labeling
events can be detected after cell lysis. Manabe and colleagues
demonstrated the value of this approach with a modified natural
product derivative in an effort to identify its protein target (Man-
abe et al., 2010). Potassium isolespedezate, a metabolite known
to induce nyctinastic leaf opening in the motor cells of plants
belonging to the Cassia genus, was derivatized with an iodoace-
tamide for covalent crosslinking to its target and an azide toiology 20, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 669
Figure 4. Identifying Protein Targets in Cell Culture
Cells grown in heavy and light media are treated with a cholesterol probe
compound that has been modified to contain a diazirine moiety. In addition,
excess cholesterol is also added to the light sample, and this will act to
complete any specific cholesterol probe-protein interactions. The cholesterol
probe is photocrosslinked to any bound protein targets in cells, and the cells
are subsequently lysed. Any cholesterol probe-protein conjugates in this
lysate are then modified with biotin using ‘click’ chemistry, and labeled pro-
teins are separated from cell lysate by affinity chromatography. The heavy and
light fractions are then mixed and examined by quantitative proteomics.
Proteins that specifically bind cholesterol will have a higher ratio of heavy to
light in the mass spectrum.
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by conjugation to a flag peptide using click chemistry. This
approach led to the identification of 5-methyltetrahydropteroyl-
triglutamate-homocysteine S-methyltransferase as the isolespe-
dezate target protein. This method, while powerful, is mostly
limited by the ability to synthesize natural product derivatives
that can covalently label their target while maintaining the
potency of the compound.
Most recently, a chemoproteomic strategy approach was
developed for the identification of PMIs for the endogenous
metabolite cholesterol. Cholesterol is a central metabolite with
roles in membrane structure, metabolism, signaling, and
disease. While many important functions of this molecule are
known, the full spectrum of proteins that interact with cholesterol670 Chemistry & Biology 20, May 23, 2013 ª2013 Elsevier Ltd All righis far from complete. Hulce and coworkers synthesized a series
of cholesterol derivatives and controls containing a photocros-
slinking diazirine group (Hulce et al., 2013; Figure 4). In practice,
cells are irradiated by light after exposure to these sterol probes,
resulting in the covalent modification of any protein they bind.
Addition of exogenous cholesterol blocks the overall labeling
of these probes to validate that binding of these probes is occur-
ring at cholesterol-specific binding sites. Subsequent to probe
labeling, the probe is conjugated to biotin by copper-catalyzed
cycloaddition of azides and alkynes (Rostovtsev et al., 2002)
chemistry, allowing for affinity enrichment of labeled proteins.
Integrating these sterol probes with SILAC (Ong et al., 2002)
enables the identification of sterol probe-target proteins. In these
experiments, the probe is added to both heavy and light cells,
but the light cells also contain a competitor (cholesterol) to block
binding. Subsequent analysis of the heavy and light samples
identifies cholesterol-binding proteins as those proteins en-
riched in the heavy sample versus the control sample. The iden-
tification of several known cholesterol-binding proteins, such as
Scap, caveolin, and 3-hydroxy-3-methyl-glutaryl-coenzyme A
reductase validated the methodology. Subsequent analysis of
the entire data set using various bioinformatics tools revealed
that almost every major class of protein has members
that bind cholesterol, including G protein-coupled receptors
(GPCRs), ion channels, and enzymes. More broadly, the analysis
also revealed an enrichment of proteins involved in neurological
disorders and cardiovascular and metabolic disease, demon-
strating the potential therapeutic insights that may eventually
be provided by these data.
Together, these examples demonstrate the utility of chemo-
proteomic approaches to identify PSMIs and PMIs and highlight
the power of these approaches to rapidly increase our under-
standing about the role of specific small molecules in biology.
Protein to Small Molecule
Biophysical Identification of Small Molecule Binders
Inmany cases, the problem of identifying a PMI beginswith inter-
est in a particular protein. This protein may be a potential drug
target, or it may be suspected to require small molecule binding
to regulate its activity. There are numerous cell-based assays for
GPCRs (Civelli, 2005; Chung et al., 2008; Allen and Roth, 2011)
and nuclear receptors (Chawla et al., 2001), for example. In gen-
eral, these methods are highly effective. Such assays have
already been reviewed extensively in the literature (Civelli,
2005; Chung et al., 2008; Allen and Roth, 2011; Chawla et al.,
2001). Instead, we’ve decided to focus on cell-free approaches
that rely heavily on biochemical, biophysical, and profiling
methods to reveal PMIs for endogenous metabolites.
Biophysical screening methods provide an effective means
for PMI discovery from endogenous metabolites. Differential
scanning techniques were originally developed to optimize
recombinant protein stability (i.e., melting temperature [Tm]) for
purification and crystallography (Vedadi et al., 2006). Differential
static light scattering (DSLS) and/or differential scanning fluorim-
etry (DSF) are the two most commonly used methods. DSLS
measured denaturation by tracking temperature-induced
increases in the intensity of scattered light, while DSF measured
increases in the fluorescence from the environmentally sensitive
dye SYPRO Orange. Shifts in melting temperatures of >2Cts reserved
Figure 5. Thermostability Shift Assay
PSMI and PMIs can be identified in a high-throughput fashion by monitoring
shifts in the Tm of a protein-ligand complex versus a protein-solvent control.
The environmentally sensitive dye SYPRO Orange emits when bound
to hydrophobic amino acid residues and is used to monitor protein unfolding
via DSF.
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tions that enhanced protein stability, and thermal shifts >4C
increased the likelihood of positive results in crystallographic
screens.
These methods have recently been extended to identify PMIs
bymeasuring the effect of small molecules on the Tmof proteins.
The binding between a small molecule and protein stabilizes
the protein structure (i.e., raises the Tm) (Figure 5). Recently,
DeSantis and coworkers used DSF to identify natural estrogen
receptor alpha (ERa) ligands from a library of molecules (not
from a complex mixture) (DeSantis et al., 2012). DSF success-
fully identified known natural ERa agonists, b-estradiol and
estrone, demonstrating the utility of this assay in characterizing
natural PMIs. The authors suggest that these assays will be use-
ful in the identification of unknown nuclear receptor ligands in the
future.
Affinity-Based Identification of Small Molecule Binders
Alternatively, affinity-based experiments using immobilized pro-
teins are another option for the characterization of PMIs. In
general, these assays provide the advantage that they can be
performed with unmodified metabolite, resulting in a reduced
likelihood of false negatives. This approach relies on the fact
that proteins can be immobilized without altering the secondary
structure of the protein or interfering with ligand binding. The first
examples of affinity methods relied on using radioisotopes to
identify PMIs by measuring radioactivity of a protein after incu-
bation and washing with a radiolabeled ligand (Sundberg,
2000; Bosworth and Towers, 1989).
Most recently, this approach has been optimized in the form of
a differential radial capillary action of ligand assay (DRaCALA),
which allows for the rapid high-throughput identification
of PMIs using radiolabeled metabolites (Roelofs et al., 2011).
DRaCALA utilizes the affinity of proteins for nitrocellulose mem-
branes to sequester radiolabeled metabolites bound to protein.
A solution containing the protein of interest and radiolabeled
ligand is spotted on nitrocellulose. Unbound ligand will diffuse
with the solvent throughout the membrane, whereas proteinChemistry & Band ligand bound to protein will be immobilized at the point it
was spotted. One advantage of DRaCALA is that it can avoid
time-consuming protein purification by using whole cell lysate
to identify PMIs as long as control cell lysate that does not
express the metabolite-binding protein is available.
The one disadvantage of this method is that it requires fore-
knowledge as to what candidate metabolites should be tested
and, in that, each metabolite must be tested individually. Never-
theless, for certain cases, DRaCALA provides a high-throughput
means to identify ligand-binding proteins. The identification of
prokaryotes that have proteins capable of binding bis-(30-50)-
cyclic dimeric guanosine monophosphate, a metabolite impor-
tant in biofilm formation, was accomplished by simply using
lysates from 191 strains of P. aeruginosa and 82 other bacterial
strains. The ‘‘hits’’ in this assay corresponded to those bacteria
that have diguanylate cyclase, as expected. This approach pre-
cludes the identification of unexpected PMIs or PMIs with novel
metabolites. Still, DRaCALA remains a powerful approach for
uncovering protein metabolite interactions.
The use of global mass spectrometry approaches allows for
the scrutiny of a larger pool of metabolites, including novel
metabolites, and can result in the unbiased identification of pro-
tein metabolite binding. Specifically, the use of global metabolite
profiling enabled the development of a novel, unbiased strategy
for the identification of endogenous PMIs (Tagore et al., 2008;
Figure 6). In this approach, recombinant proteins fused to an
affinity tag—either GST or hexahistidine—are immobilized on a
solid support. Incubation of these proteins with a metabolite
mixture, typically an extract containing the entire lipidome from
a cell or tissue of interest results in the formation of a protein-
metabolite complex on the bead. Following this incubation, the
protein is washed, subsequently eluted from the solid support,
and the eluent is then analyzed using a liquid chromatography-
mass spectrometry (LC-MS) metabolite profiling platform (using
an electrospray ionization-time of flight for the MS). Quantitative
comparison of themetabolite profiles between samples with and
without protein reveals any metabolites that are enriched by the
protein.
This approach was developed using three different lipid-
binding proteins with known ligands: cytosolic retinoic acid-
binding protein 2, fatty acid-binding protein 2, and StarD3. The
strategy successfully identified specific PMIs for all three of
these proteins and, in doing so, created a reliable method to
pull down protein metabolite interactions (Tagore et al., 2008).
It does not require any explicit knowledge about the identity of
the metabolite and can be conducted rapidly against a large
pool of metabolites. Moreover, it was not susceptible to the
enrichment of nonspecific metabolites. Although the examples
presented here centered on lipids, there is no reason this
approach could not be used for polar metabolites as well. This
strategy has been successfully applied to other PMIs, including
the discovery that arachidonic acid and docosahexanoic acid,
polyunsaturated fatty acids, bind to the orphan nuclear receptor
Nur77 (Vinayavekhin and Saghatelian, 2011).
Li and colleagues developed an exciting strategy to identify
PMIs within yeast (Li et al., 2010; Figure 6). Specifically, they
focused on interaction with yeast protein kinases as well as pro-
teins that comprise ergosterol pathway. The proteins in this
group were epitope tagged to enable their immunoprecipitationiology 20, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 671
Figure 6. Affinity Methods for Elucidating PMIs
(A) Protein (blue) is immobilized on a solid support (gray)
and incubated with lipids from tissue lysate. The immo-
bilized protein is then washed and the protein is eluted
from the beads. The eluate is then analyzed by LC-MS
and compared to eluate from a control sample (solid
support with no protein) in order to identify specific PMIs.
(B) A yeast strain bearing either the protein of interest
fused to an immunoglobulin G (IgG) epitope tag or the IgG
epitope tag only was lysed and immunoprecipitated
using antibody-labeled beads. Lipids were then
extracted from the beads and examined by LC-MS.
Comparison between the protein and control sample can
be used to identify any specific PMIs.
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analyzed by metabolomics to identify any endogenous metabo-
lites bound to the proteins. As a control, each sample was also
checked by SDS-PAGE to ensure pull-down of the target protein
was successful.
Comparison of themetabolite profiles from these various sam-
ples revealed a number of new interactions. Many of the
enzymes within the ergosterol pathway bound to sterol interme-
diates, which suggests that these molecules exert regulation on
the pathway. Interestingly, it was also discovered that some of
the proteins within the ergosterol pathway bind to pentaporphor-
yin, which was a complete surprise but helps explain a previous
observation linking pentaporphoryin and ergosterol regulation.
Furthermore, their analysis led to the discovery that a number
of yeast protein kinases are regulated by ergosterol to highlight
the generality of this method toward numerous protein classes.
In aggregate, these data highlight the potential for unbiased
PMI identification to greatly increase our current understanding
of endogenous small molecule biology.
Future Directions
A successful library of approaches to determine PSMIs and PMIs
has been developed and is ready to be applied to identify
unknown PMIs of interest. These approaches enable the discov-
ery of novel interactions and are also designed to maximize the
likelihood that the interactions are occurring in cells and tissues.
The continued application of these methods will enrich our
understanding of small molecule biology and also stimulate the
development of improved methods for discovering these inter-
actions. As demonstrated by the above examples, this research
area sits squarely at the interface of chemistry and biology and
will greatly benefit from collaboration between future genera-
tions of chemists, biochemists, and biologists.672 Chemistry & Biology 20, May 23, 2013 ª2013 Elsevier Ltd All righREFERENCES
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